What happens when doctors stop prescribing temazepam? Use of alternative therapies

THOMAS C GILHOLLY
MARY G O WEBSTER
NORMAN W POOLE
SUE ROSS

SUMMARY
We investigated the withdrawal of temazepam in a single general practice using two alternative prescribing policies: an alternative benzodiazepine; or an alternative group of drugs recommended for short-term management of insomnia, including sedative antihistamines and chloral hydrate. The study showed that temazepam prescribing in general practice can be reduced or stopped by using a simple intervention. An alternative benzodiazepine is useful in helping patients to stop their use of hypnotic agents. The use of antihistamines as substitute hypnotics is not advocated on the basis of our findings.

Keywords: prescribing; sleep disorders; benzodiazepines; hypnotic agents; intervention.

Introduction
Concern about misuse of temazepam, combined with evidence that National Health Service (NHS) prescriptions were the main source of supply, led us to investigate the withdrawal of temazepam in a single general practice. We decided to replace temazepam with two groups of hypnotics with lower abuse potential: an alternative benzodiazepine or an alternative group of drugs recommended for short-term management of insomnia, including sedative antihistamines (some of which are widely available as over-the-counter hypnotics) and chloral hydrate. The aim of the study was to investigate whether temazepam prescribing could be stopped using alternative drugs as substitutables, and to discover if there were any differences in outcome between the two substitution policies.

Method
From 1 February 1995, all patients requesting a prescription for temazepam (excluding one patient who was considered too unwell) were given a study number: odd numbered patients were allocated to receive an antihistamine replacement or chloral hydrate (antihistamine/chloral group), and even numbered patients received a benzodiazepine replacement (benzodiazepine group) (Appendix 1). All patients were also given information on reducing their dose of temazepam and advice on healthy sleeping. The option of remaining on temazepam was not offered.

Nineteen months after temazepam withdrawal, each patient was followed up by the research nurse (MW) and invited to take part in a home interview.

Results
Ninety-one patients were recruited: 46 were allocated to the antihistamine/chloral group, 45 to the benzodiazepine group. The characteristics of the study groups were similar at the time of recruitment (Table 1). A similar number of patients in each group were interviewed: 36 (78%) of the antihistamine/chloral group, 38 (84%) of the benzodiazepine group.

Of the antihistamine/chloral group, 32 (70%) were initially changed to one of the recommended antihistamines; 28 (62%) of the benzodiazepine group were prescribed one of the recommended benzodiazepines. Only eight out of 36 (22%) of the antihistamine/chloral group, seven patients of 32 (22%) in the antihistamine group, seven patients of 38 (19%) were still taking antihistamines. Of those interviewed, one of the 36 (3%) in the antihistamine/chloral group, and nine out of 38 (24%) in the benzodiazepine group, had stopped hypnotic treatment altogether (Fisher’s exact P = 0.014).

Discussion
This study demonstrated that general practitioners (GPs) can stop prescribing temazepam with the help of a simple intervention consisting of a brief description of a detoxification routine along with substitute hypnotic therapy. The results indicate that a policy of prescribing an alternative benzodiazepine is preferable to substitution by antihistamine or chloral hydrate, because significantly more patients reported being satisfied with the change in treatment and more stopped taking hypnotics altogether.

Although potentially flawed, the method of treatment allocation was selected for practical reasons; when compared, the two groups proved to be well balanced (Table 1). Despite being selected from an area of high multiple deprivation, the practice population of temazepam users was similar to benzodiazepine users reported in other studies, predominantly consisting of elderly women with considerable co-morbidity and who had been prescribed temazepam for some time. It is likely that this population will be intrinsically difficult to treat, and so the success in reducing temazepam prescribing is particularly welcome.

Sedative antihistamines (diphenhydramine, promethazine) are freely available for sale to the public ‘for occasional insomnia in adults’ and are widely advertised as such. Our study demonstrated that the antihistamine/chloral group were less satisfied with their original treatment and had more changes of medication, implying a cost to GPs. Seven patients remained on long-
term use of antihistamine, only three of whom reported being satisfied with their treatment. Our study does not support the use of antihistamines as a substitute for benzodiazepines and would question their use as a short-term hypnotic.

Benzodiazepine substitution was the preferred option, resulting in 24% of interviewees taking no hypnotic therapy 19 months after temazepam prescribing stopped — a similar outcome to the work of the characteristics of long-term benzodiazepine users in general practice.

In conclusion, this study shows that temazepam prescribing in general practice can be reduced. An alternative benzodiazepine is useful in helping some patients stop their hypnotic use, but further work is needed to identify the characteristics of patients who would best respond to this form of treatment, or if the findings can be extrapolated to other benzodiazepine users. The use of antihistamines as substitute hypnotics is not advocated on the basis of our findings.

### References


### Acknowledgements

We thank Professor Graham Watt and Dr Neil Drummond for their helpful comments on the manuscript, and Dr Nathaniel Rifkind for collaborating in the study. Follow-up of patients was funded by the Health Services and Public Health Research Committee of the Scottish Office Department of Health.

### Address for correspondence

Dr Sue Ross, Clinical Trials Programme Coordinator, Health Services Research Unit, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD.